ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AVCT Avacta Group Plc

48.50
-0.50 (-1.02%)
Last Updated: 12:18:47
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.02% 48.50 48.00 49.00 48.75 47.50 48.75 1,572,430 12:18:47
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 10.06M -39.19M -0.1382 -3.53 138.26M
Avacta Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 49p. Over the last year, Avacta shares have traded in a share price range of 47.50p to 166.50p.

Avacta currently has 283,614,110 shares in issue. The market capitalisation of Avacta is £138.26 million. Avacta has a price to earnings ratio (PE ratio) of -3.53.

Avacta Share Discussion Threads

Showing 4201 to 4225 of 79650 messages
Chat Pages: Latest  174  173  172  171  170  169  168  167  166  165  164  163  Older
DateSubjectAuthorDiscuss
10/4/2019
13:09
Just to remind everybody Moderna is presenting today at the Needham conference
hampton58
09/4/2019
17:21
yes, I do believe they will young man :-) cheers Wan lol
wanobi
09/4/2019
16:59
Jam, jam and more jam but will they ever deliver!?
killieboy
09/4/2019
15:02
The mRNA platform is a promising medical technology which have attracted a wave of interest and partnerships from the majors and with Moderna now taking the partnership with Avacta forward , exciting times ahead.The sector will push valuations up and Astra Zeneca Merck,Sanofi etc are investing.Watch this space.
hampton58
09/4/2019
14:53
Interesting reaction to today's results.With Details of the upfront payment from LG Chem license agreement and clearly further license deals in the pipeline, combined this with the recent confirmation of Moderna having exercised its option to take the license agreement further, makes this mRNA play a very attractive area to be involved in.The mRNA equities, Moderna etc have had a significant uplift over the last couple of weeks. Moderna is up +35% in the last week or so.Recent publications in prestigious journals, shows that if it is proven that the mRNA encoded protein synthesis works in animals is extended to humans, a $200 billon recombinant protein industry is being disrupted.Previous data have shown Affimets seem to be good for encoded delivery.
hampton58
09/4/2019
10:51
"Plenty of cash in the bank"...plenty of cash to come, look at the ridiculous market cap and DYOR.
1i1i1i
09/4/2019
10:49
hxxps:// www.proactiveinvestors.co.uk/companies/news/218211/avacta-well-cashed-and-on-track-to-begin-clinical-trial-of-first-affimer-therapeutic-next-year-218211.html


Avacta well-cashed and on track to begin clinical trial of first Affimer therapeutic next year

11:40 09 Apr 2019 The first Affimer-based therapeutic is PD-L1 is a potential cancer treatment that helps the immune system to identify and attack cancer cells

Affimers have both therapeutic and non-therapeutic uses

Avacta Group PLC (LON:AVCT) remains on track to begin a Phase I clinical trial of its first Affimer therapeutic candidate next year.

Affimers are small, engineered proteins that are capable of binding specific molecular targets, in a similar way to antibodies.

READ: Avacta says partner Moderna takes collaboration to next level

The proteins are smaller, quicker to manufacture and easier to format than antibodies, but they maintain antibody-like biologic activity when binding a target.

Avacta thinks the technology has both therapeutic and non-therapeutic applications.

The AIM company is already using Affimers to develop various potential cancer treatments, while other companies pay to use the technology in their research and diagnostics.

Avacta has selected a PD-L1 inhibitor as the first Affimer-based potential cancer therapeutic that it is taking through the clinic.

PD-L1 is a checkpoint protein that essentially provides a cloak for the cancer cells, helping them to evade detection by the immune system.

Start dosing in Q4 2020

The company is soon to start manufacturing its PD-L1 inhibitor – called AVA004-251 – which will then allow it to file a clinical trial application, asking regulators to let it test the drug on humans.

That filing is expected to happen in late 2020 and the plan is to start dosing the first patients in a Phase I dose escalation study in the final quarter of next year.

“The group remains focused on the key objective of first-time-in-human data for the Affimer therapeutic programme and growing a profitable Affimer reagents business,” said chief executive Alastair Smith.

“First-time-in-human data is a significant value inflection point for the technology and a major de-risking point from a deal-making perspective. The group remains on track, to a tight schedule, to dose first patients in late 2020.”

Plenty of cash in the bank

For the six months ended 31 January, Avacta recorded revenues of £1.0mln (H1 18: £1.5mln), although the new licensing deal with LG Chem will boost second-half numbers.

Unsurprisingly, R&D costs rose to £2.4mln (H1 18: £1.5mln) in the period, which meant operating losses climbed to £5.9mln (H1 18: £4.5mln).

Thanks to an £11.6mln fundraise in August, cash on hand totalled £11.8mln at the end of January (H1 18: £5.2mln).

In a note to clients, analysts at ‘house’ broker finnCap commented: “Significant progress continues to be made in non-therapeutic applications that include at least two in-house diagnostic assay development programmes with further licence

1i1i1i
09/4/2019
08:47
Then move on Poacher, $2.5m received, $5.5m due in the near term, cash in the bank and multiple deals in the pipeline, good enough for me.
1i1i1i
09/4/2019
08:39
Was it 10 years ago they forcast a profit for the next year. Still the same old story turnover lower or stagnated. Losses higher every year. Always jam tommorrow.
poacher45
09/4/2019
07:55
How much lower will it go.. fancy a top up.
losses
09/4/2019
07:30
Typical short termism... buying opportunity.
bonzo
09/4/2019
07:28
Results didn't go down well..
losses
09/4/2019
07:28
Slower progress than hoped for - Not liked by market - Down 10% - Long term jury still out - Could be some more profit preservation to come by those who took part in the placing (imo)
pugugly
09/4/2019
06:21
"Strong focus on generating further license deals during 2019 arising from multiple ongoing technology evaluations." I like the word multiple ;-)
1i1i1i
09/4/2019
06:18
Less upfront ($2.5m) and near term ($5.5m) than I'd hoped for in a $300m deal, but as the first deal it provides a baseline for future deals.

Remains the most likely 100-bagger in my portfolio, though obviously has the associated risks of any fledgling biotech.

Market cap is still nothing more than pocket change to large pharma.

the drewster
08/4/2019
15:32
Not correct At the AGM the company mentioned that they would not release details of the upfront payment until interims numbers.ie. tomorrow So we should more details tomorrow.
hampton58
08/4/2019
15:06
I thought LG had requested no detail be released so I don't expect to read anything new tomorrow.
toffeeman
08/4/2019
14:56
In the initial RNS they mentioned an upfront payment , but more important there would further near term milestone paymentsShould be very interesting tomorrow AM
hampton58
08/4/2019
14:47
Keeping these next 4-5 years
losses
08/4/2019
14:26
They said so verbally at at least one of the presentations.
the drewster
08/4/2019
14:20
Did they say somewhere that further detail on the deal with LG would be disclosed in the results?
mortimer7
08/4/2019
13:21
YesShould see further upside tomorrow testing March highs
zebrano10
08/4/2019
10:50
Looking perky this morning.
losses
08/4/2019
09:00
YesWill be Interesting read indeedI suspect additional ongoing talks are taking place with other parties generating potential further contractsCould be a good day tomorrow
zebrano10
08/4/2019
08:35
Results tomorrow which will include the LG payment.
1i1i1i
Chat Pages: Latest  174  173  172  171  170  169  168  167  166  165  164  163  Older

Your Recent History

Delayed Upgrade Clock